Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat
different types of cancer. There will be several different types of cancer studied in the
trial. The cancer must have spread to other parts of the body (metastatic) and must have
gotten worse (progressed) after being treated with a PD-1 inhibitor treatment.
The study will also find out what side effects occur. A side effect is anything the treatment
does besides treat cancer.
This is a multi-cohort study.